Circulating renalase predicts all-cause mortality and renal outcomes in patients with advanced chronic kidney disease

Baek, Seon Ha; Hui, Ran; Kang, Shin Wook; Park, Cheol Whee; Ryong, Dae; Kim, Sung Gyun; Yoon, Sun Ae; Kim, Sejoong; Han, Sang Youb; Park, Jung Hwan; Chang, Jae Hyun; Lim, Chun Soo; Kim, Yon Su; Na, Ki Young

doi:10.3904/kjim.2017.058

Cited by 24 publications

(26 citation statements)

References 35 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, we also observed that a low post-PCI serum renalase level could predict a lower risk for the composite endpoint including a first episode of myocardial infarction, stroke, and all-cause mortality. In line with our longitudinal follow-up findings for patients with established CAD, high baseline serum renalase levels were found to predict a high risk of all-cause mortality in patients with CKD in a prospective observational study [ 21 ], although a low plasma renalase concentration was observed in patients with CAD in a cross-sectional study [ 29 ].…”

Section: Discussionsupporting

confidence: 79%

“…Renalase produced by the kidney is a flavin-adenine-dinucleotide-dependent amine oxidase that metabolizes catecholamines [ 20 ]. The circulating concentration of renalase is reportedly increased in patients with chronic kidney disease (CKD) and might predict mortality in this population [ 21 ]. CAD is prevalent in patients with CKD, and the pathogenesis between CAD and CKD is complex [ 22 , 23 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum Renalase Levels Are Predicted by Brain-Derived Neurotrophic Factor and Associated with Cardiovascular Events and Mortality after Percutaneous Coronary Intervention

Lee

Sheu

2018

JCM

View full text Add to dashboard Cite

Circulating brain-derived neurotrophic factor (BDNF) predicts survival rate in patients with coronary artery disease (CAD). We examined the relationship between BDNF and renalase before and after percutaneous coronary intervention (PCI) and the role of renalase in patients with CAD. Serum BDNF and renalase levels were determined using blood samples collected before and after PCI. Incident myocardial infarction, stroke, and mortality were followed up longitudinally. A total of 152 patients completed the assessment. BDNF levels were not significantly changed after PCI compared to baseline levels (24.7 ± 11.0 vs. 23.5 ± 8.3 ng/mL, p = 0.175), although renalase levels were significantly reduced (47.5 ± 17.3 vs. 35.9 ± 11.3 ng/mL, p < 0.001). BDNF level before PCI was an independent predictor of reduction in renalase (95% confidence interval (CI): −1.371 to −0.319). During a median 4.1 years of follow-up, patients with serum renalase levels of ≥35 ng/mL had a higher risk of myocardial infarction, stroke, and death than those with renalase of <35 ng/mL (hazard ratio = 5.636, 95% CI: 1.444–21.998). In conclusion, our results show that serum BDNF levels before PCI were inversely correlated with the percentage change in renalase levels after PCI. Nevertheless, post-PCI renalase level was a strong predictor for myocardial infarction, stroke, and death.

show abstract

Section: Discussionsupporting

confidence: 79%

Section: Introductionmentioning

confidence: 99%

Serum Renalase Levels Are Predicted by Brain-Derived Neurotrophic Factor and Associated with Cardiovascular Events and Mortality after Percutaneous Coronary Intervention

Lee

Sheu

2018

JCM

View full text Add to dashboard Cite

show abstract

“…The elevation in serum renalase has been also repeatedly associated with heart and circulatory dysfunctions, very common in the CKD, since heart seems to be another very important source of RNLS. Low concentration of renalase is considered as one of the predictive factors of coronary artery disease (CAD) [8,12,22], and an increase in serum renalase is associated with significantly greater hazards of all-cause mortality and adverse renal outcomes [23]. In our study, the presence of hypertension or any of cardiovascular disease had no impact on renalase concentration.…”

Section: Discussionmentioning

confidence: 57%

Serum-to-urine renalase ratio and renalase fractional excretion in healthy adults and chronic kidney disease patients

et al. 2020

View full text Add to dashboard Cite

Background: Renalase is a flavoprotein that plays a protective role in chronic kidney disease (CKD) and cardiovascular diseases. The secretion and way of action of this protein are still discussed. The aim of our study was to estimate the balance between serum and urine renalase in healthy individuals and CKD patients, using two parameters: fractional excretion (FE) and serum-to-urine renalase ratio (StURR). Methods: Our study involved 28 healthy volunteers and 62 patients with CKD in stages I to IV. The concentration of renalase in serum and urine was measured using an enzyme-linked immunosorbent assay (ELISA) kit (EIAab, Wuhan, China). We analyzed associations between renalase levels in urine and serum, and other parameters: sex, age, GFR, presence of hypertension, diabetes, and proteinuria, and determined the serum-to-urine renalase ratio and fractional excretion of renalase. Results: Renalase and serum-to-urine ratio were significantly higher in CKD patients in comparison with the control group. Fractional excretion was lower in CKD patients but this difference did not reach the statistical significance (p = 0.092). Multivariate analysis performed in the CKD group showed, that from mentioned parameters, serum renalase was the only significant independent factor strongly positively associated with urinary renalase concentration. Conclusions: The serum-to-urine ratio is significantly and about 6.5-fold higher in CKD patients, and the fractional excretion of renalase is 3-fold, but not significantly lower in CKD patients. Renalase levels in both serum and urine are not related to the glomerular filtration rate and not associated with blood pressure.

show abstract

“…Low concentration of renalase is considered as one of the predictive factors of coronary artery disease (CAD) (8,12,23), and an increase in serum renalase is associated with significantly greater hazards of all-cause mortality and adverse renal outcomes (24). In our study, the presence of hypertension or any of cardiovascular disease had no impact on renalase concentration.…”

Section: Discussionmentioning

confidence: 57%

Serum-to-urine renalase ratio and renalase fractional excretion in healthy adults and chronic kidney disease patients.

Serwin

Wiśniewska

Cecerska-Heryć

et al. 2019

Preprint

View full text Add to dashboard Cite

Background: Renalase is a flavoprotein that plays a protective role in chronic kidney disease and cardiovascular diseases. The secretion and way of action of this protein are still discussed. The aim of our study was to estimate the balance between serum and urine renalase in healthy individuals and chronic kidney disease (CKD) patients, using two parameters: fractional excretion (FE) and serum-tourine renalase ratio (StURR). Methods: Our study involved 28 healthy volunteers and 62 patients with CKD in stages I to IV. The concentration of renalase in serum and urine was measured using an enzyme-linked immunosorbent assay (ELISA) kit (EIAab, Wuhan, China). We analyzed associations between renalase levels in urine and serum, and other parameters: sex, age, GFR, presence of hypertension, diabetes, and proteinuria, and determined the serum-to-urine renalase ratio and fractional excretion of renalase. Results: Renalase and serum-to-urine ratio were significantly higher in CKD patients in comparison with the control group. Fractional excretion was lower in CKD patients but this difference did not reach the statistical significance (p=0.092). Multivariate analysis performed in the CKD group showed, that from mentioned parameters, serum renalase was the only significant independent factor strongly positively associated with urinary renalase concentration. Conclusions:The serum-to-urine ratio is significantly and about 6.5-fold higher in CKD patients, and the fractional excretion of renalase is 3-fold, but not significantly lower in CKD patients. Renalase levels in both serum and urine are not related to glomerular filtration rate and not associated with blood pressure.

show abstract

Circulating renalase predicts all-cause mortality and renal outcomes in patients with advanced chronic kidney disease

Cited by 24 publications

References 35 publications

Serum Renalase Levels Are Predicted by Brain-Derived Neurotrophic Factor and Associated with Cardiovascular Events and Mortality after Percutaneous Coronary Intervention

Serum Renalase Levels Are Predicted by Brain-Derived Neurotrophic Factor and Associated with Cardiovascular Events and Mortality after Percutaneous Coronary Intervention

Serum-to-urine renalase ratio and renalase fractional excretion in healthy adults and chronic kidney disease patients

Serum-to-urine renalase ratio and renalase fractional excretion in healthy adults and chronic kidney disease patients.

Contact Info

Product

Resources

About